Insights

Innovative Therapeutics TransCode Therapeutics is advancing a proprietary delivery platform and targeted therapeutics aimed at microRNA-10b, which plays a central role in tumor metastasis. Their focus on pioneering treatments for high-need cancers such as breast, pancreatic, and glioblastomas presents opportunities to collaborate or supply advanced drug delivery solutions for oncology markets.

Strategic Expansions Recent acquisitions of Polynoma LLC and licensing agreements for multiple oncolytic adenovirus candidates indicate aggressive growth and diversification within their pipeline. This expansion broadens potential avenues for partnership with biotech firms, contract research organizations, or suppliers of immuno-oncology and gene therapy technologies.

Funding and Growth With a recent financing of $1.5 million and a total funding of $10 million, TransCode is positioned for continued research and clinical development. This financial stability suggests ongoing opportunities for vendors or service providers to support their clinical trials, manufacturing, and regulatory efforts.

Leadership and Innovation New leadership appointments, including a Chief Executive Officer and key senior development personnel, reflect strategic focus and potential for accelerated development timelines. Engaging with their management team or consultants could facilitate partnerships in clinical development, research, or technological innovation.

Industry Positioning Operating in the competitive biotech landscape with recent clinical milestones and licensing deals, TransCode is establishing itself as a key player in targeted cancer therapies. This presents potential channels for sales of biotech tools, research reagents, or partnership opportunities in co-developing next-generation oncology treatments.

Similar companies to TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Tech Stack

TransCode Therapeutics, Inc. uses 8 technology products and services including Google Fonts API, Mustache, jQuery, and more. Explore TransCode Therapeutics, Inc.'s tech stack below.

  • Google Fonts API
    Font Scripts
  • Mustache
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • ScrollReveal
    Javascript Libraries
  • reCAPTCHA
    Security
  • Cloudflare Bot Management
    Security
  • Adobe Fonts
    Web Fonts
  • Apache
    Web Servers

Media & News

TransCode Therapeutics, Inc.'s Email Address Formats

TransCode Therapeutics, Inc. uses at least 1 format(s):
TransCode Therapeutics, Inc. Email FormatsExamplePercentage
First.Last@transcodetherapeutics.comJohn.Doe@transcodetherapeutics.com
92%
Last@transcodetherapeutics.comDoe@transcodetherapeutics.com
5%
Last.F@transcodetherapeutics.comDoe.J@transcodetherapeutics.com
3%

Frequently Asked Questions

Where is TransCode Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s main headquarters is located at 73b Chapel Street Newton, Massachusetts 02458 United States. The company has employees across 2 continents, including North AmericaEurope.

What is TransCode Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s official website is transcodetherapeutics.com and has social profiles on LinkedInCrunchbase.

What is TransCode Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does TransCode Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of April 2026, TransCode Therapeutics, Inc. has approximately 16 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: Q. L.Ceo & Chairman, Transcode Therapeutics (nasdaq: Rnaz): P. C.Chief Technology Officer: Z. M.. Explore TransCode Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does TransCode Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does TransCode Therapeutics, Inc. use?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s tech stack includes Google Fonts APIMustachejQueryScrollRevealreCAPTCHACloudflare Bot ManagementAdobe FontsApache.

What is TransCode Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s email format typically follows the pattern of First.Last@transcodetherapeutics.com. Find more TransCode Therapeutics, Inc. email formats with LeadIQ.

How much funding has TransCode Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of April 2026, TransCode Therapeutics, Inc. has raised $10M in funding. The last funding round occurred on Mar 23, 2025 for $10M.

When was TransCode Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. was founded in 2016.

TransCode Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

TransCode's goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. 

TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Important Notice: Recruitment Fraud Alert
We are aware of recruitment scams in which fraudsters pose as representatives of TransCode Therapeutics to deceive job seekers. Please note the following to protect yourself:
    •    We NEVER ask for payment or personal financial information during the recruitment process.
    •    All legitimate communication from our team will come from an official @transcodetherapeutics.com email address 
    •    Our hiring process always includes formal interviews—either virtual or in-person.
    •    If you receive a  job offer claiming to be from us, please do NOT respond. Report it to info@transcodetherapeutics.com.

Section iconCompany Overview

Headquarters
73b Chapel Street Newton, Massachusetts 02458 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.